Guselkumab provides durable improvement across psoriatic arthritis disease domains: Post hoc analysis of a Phase 3, randomised, double-blind, placebo-controlled study
RMD Open 2024;10:e003977 doi: 10.1136/rmdopen-2023-003977
Significant improvements in overall disease activity, enthesitis and dactylitis, and skin psoriasis were observed by Week 8 and maintained or improved through Week 100 in both guselkumab treatment groups. Coates et al conducted a post-hoc analysis of the Phase 3 DISCOVER-2 trial to investigate the long-term (100-week) efficacy of guselkumab across GRAPPA-identified PsA domains.
Patients displayed baseline disease activity scores consistent with highly active PsA and achievement of therapeutic targets improved continuously through Week 100.
Keywords:
